{"entity":{"id":"nct06858410","kind":"trial","name":"Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma","aka":[],"tldr":"A phase 3 trial of lorlatinib in lung cancer, run by Guangdong Association of Clinical Trials, not yet recruiting.","summary":"Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma is a phase 3, randomised interventional study registered as NCT06858410 by Guangdong Association of Clinical Trials, with a registry enrolment figure of 36 participants, started 2025-03 and due to reach its primary completion in 2030-03. Interventions recorded: lorlatinib; concurrent/sequential platinum-based chemoradiotherapy. Conditions listed: Neoadjuvant Non-Small Cell Lung Cancer. Primary outcome: Progression Free Survival (PFS). Lung eligibility wording from the registry: \"* Study Population: Patients with histologically or cytologically confirmed diagnosis of ALK-positive, lung adenocarcinoma who present with locally advanced, unresectable (Stage III) disease (according to Version 8 of the International Association for the Study of Lung Cancer \\[IASLC\\])\". No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06858410","url":"https://clinicaltrials.gov/study/NCT06858410"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["alk-positive-nsclc","stage-iii-unresectable-nsclc"],"sections":[],"technologies":["imrt-igrt","kinase-inhibitors"],"targets":[],"drugs":["lorlatinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06858410","phase":"3","setting":"A Randomized, Open-label, Multicenter, Phase III Study of Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy As Definitive Treatment in Patients with Locally Advanced, Unresectable Stage III ALK Positive Lung Adenocarcinoma","sponsor":"Guangdong Association of Clinical Trials","enrolled":36,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06858410/","neighbours":{"cancer":[{"id":"alk-positive-nsclc","kind":"cancer","name":"ALK-positive non-small-cell lung cancer","route":"/cancers/alk-positive-nsclc/"},{"id":"stage-iii-unresectable-nsclc","kind":"cancer","name":"Unresectable stage III non-small-cell lung cancer","route":"/cancers/stage-iii-unresectable-nsclc/"}],"technology":[{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"lorlatinib","kind":"drug","name":"Lorlatinib","route":"/drugs/lorlatinib/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}